BRIEF-Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track Designation In Systemic Lupus Erythematosus (Sle)

Johnson & Johnson +0.32%

Johnson & Johnson

JNJ

240.40

+0.32%

- Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON THERAPY NIPOCALIMAB GRANTED U.S. FDA FAST TRACK DESIGNATION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Source text: ID:nPn4tP9fla

Further company coverage: JNJ.N


Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via